Skip to main content
by learnformula
Explore courses
search
For Business
Team license & compliance management
For Higher Education
Academic partnerships
For Government Agencies
Government training solutions
For Instructors & Course Creators
Teach on our marketplace
Become a Sponsor
Reach professionals where they learn
Log inStart 7-Day Free TrialStart Free TrialStart Free Trial
search
Explore courses
arrow_backBack to Latest Intelligence

The FDA Expertise Premium: What K&L Gates' Washington Hire Signals for Life Sciences Law Practice

Julia Reynolds•Nov 22, 2026•
8 min read
Share
SIGN UP AND GET
10% OFF
Sign up for our newsletter and get 10% off your next purchase!
By subscribing, I agree to LearnFormula's email marketing. I can unsubscribe anytime. See Privacy Policy.

In a regulatory environment where a single agency letter can reshape a drug launch timeline or a device company's valuation overnight, the most valuable lawyer in the room is often the one who previously sat on the other side of the table. That dynamic is at the center of K&L Gates' announcement that it has added former FDA regulatory counsel Christine Kirk as a partner in its Washington, D.C. office, expanding its Healthcare and FDA practice.

The Hire: What Was Announced

According to the firm's announcement, Kirk joins K&L Gates from the agency's legal side and will counsel biopharmaceutical and life sciences clients in Washington. The announcement is brief, and the public summary does not detail her specific practice areas, prior FDA centers, or client matters. Practitioners evaluating the move should treat it as a signal of strategic direction rather than a full picture of her portfolio.

The signal itself is clear. Firms are competing for lawyers who understand how FDA reviewers think, how agency counsel evaluate legal arguments, and where enforcement risk actually originates. That knowledge is difficult to build from outside the agency and is increasingly treated as a core competitive asset.

Why Former FDA Counsel Command a Premium

FDA practice sits at the intersection of statute, regulation, guidance, and sheer procedural complexity. The Federal Food, Drug, and Cosmetic Act provides the framework, but much of day-to-day compliance risk lives in agency guidance documents, review correspondence, inspection findings, and the informal expectations that shape how applications move through review.

Insider Understanding of Agency Process

Former agency lawyers know how decisions are made internally, which offices weigh in on which questions, and how an argument that looks strong on paper may fare in practice. That perspective shapes everything from how a regulatory strategy is framed to how a company responds when the agency signals concern.

Enforcement and Inspection Exposure

Life sciences companies face multiple enforcement touchpoints, including inspection observations, warning letters, and import actions. Lawyers who have worked inside the enforcement apparatus are often better positioned to assess whether a finding is likely to escalate, how to respond in a way that limits downstream consequences, and when a dispute is worth pursuing.

Litigation Risk After Loper Bright

The Supreme Court's 2024 decision in Loper Bright Enterprises v. Raimondo ended Chevron deference, meaning courts now independently interpret statutes rather than deferring to reasonable agency readings. For life sciences clients, this has increased the importance of statutory arguments and of building records that will hold up under independent judicial review. Former agency counsel bring a practical sense of which agency interpretations are most vulnerable and which are defensible.

The addition highlights growing law firm investments in specialized regulatory talent to counsel biopharmaceutical and life sciences clients. (K&L Gates announcement summary)

Mapping the Value of Regulatory Hires

The following table outlines the practical areas where former FDA counsel typically add value for clients. It is a general framework, not a description of Kirk's specific responsibilities.

Practice AreaTypical Client NeedValue of Former Agency Experience
Pre-market strategyApproval pathway planning and sponsor-agency communicationsAnticipates reviewer concerns and shapes submissions accordingly
Enforcement responseInspection observations and warning letter repliesAssesses escalation risk and frames credible corrective actions
Advertising and promotionLabeling, promotional claims, and off-label communicationsIdentifies agency sensitivities before a complaint or letter arrives
Transactional diligenceM&A and financing involving regulated productsEvaluates regulatory risk in target companies with greater precision
Litigation supportChallenges to agency actions and product liability overlapIdentifies procedural and substantive vulnerabilities in agency positions
Key TakeawayFormer agency counsel are becoming a strategic necessity, not a luxury. In a post-Chevron world, the ability to anticipate how the FDA will read a statute, a guidance document, or an inspection record is a direct driver of client outcomes.

Washington as the Regulatory Nerve Center

K&L Gates' choice of Washington, D.C. is consistent with how life sciences regulatory work is organized. Many agency decision-makers, trade associations, and congressional committees with jurisdiction over health policy are concentrated in the capital, and proximity matters for both formal and informal engagement. For clients with pending applications, legislative exposure, or policy stakes, a D.C.-based FDA practitioner offers access that remote counsel cannot easily replicate.

The hire also reflects the growing overlap between FDA regulation and broader health policy. Drug pricing debates, reimbursement questions, and the regulation of digital health tools increasingly intersect with traditional FDA work, and firms that can advise across those boundaries are better positioned to win mandates.

Practical Implications for U.S. Life Sciences Counsel

For practitioners and in-house teams, the announcement offers several lessons worth acting on:

  1. Audit your regulatory bench depth. Companies with a single gatekeeper for FDA matters are exposed if that person leaves or becomes unavailable during a critical review cycle.
  2. Map enforcement touchpoints early. Inspection observations and correspondence from the agency should trigger a structured legal assessment, not just a technical response.
  3. Build statutory arguments into regulatory strategy. After Loper Bright, agency positions may be challenged more directly, so records and submissions should anticipate independent judicial review.
  4. Evaluate counsel on agency fluency. When selecting outside counsel, ask how the team has engaged with the relevant FDA centers and whether its lawyers understand internal review dynamics.
  5. Integrate regulatory risk into deal diligence. Transactions involving regulated products should include an assessment of enforcement history, pending correspondence, and approval pathway risk.

Looking Ahead

The Kirk hire is one data point in a larger pattern: firms are investing in specialized regulatory talent because clients need advisors who can operate at the seam between law, science, and agency judgment. For U.S. life sciences lawyers, the competitive question is no longer whether to build regulatory depth but how quickly they can do it. Expect more lateral moves from agency alumni, more firms positioning D.C. offices as life sciences hubs, and a steady premium on lawyers who can translate agency behavior into actionable client strategy. Companies that treat regulatory counsel as a strategic function rather than a compliance cost will be better prepared for the scrutiny ahead.